PE anti-human CD19 Antibody

Pricing & Availability
Clone
HIB19 (See other available formats)
Regulatory Status
RUO
Workshop
V CD19.11
Other Names
B4
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
HIB19_PE_061807
Human peripheral blood lymphocytes stained with HIB19 PE
  • HIB19_PE_061807
    Human peripheral blood lymphocytes stained with HIB19 PE
Compare all formats See PE spectral data
Cat # Size Price Save
302207 25 tests ¥6,160
302208 100 tests ¥12,440
302254 100 µg ¥16,060
Description

CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The CD19 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections8 and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302267 & 302268).

 

Clone HIB19 partially blocks anti-human CD19 clones 4G7 and SJ25C1 staining based on in-house testing

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  3. Bradbury L, et al. 1993. J. Immunol. 151:2915.
  4. Joseph A, et al. 2010. J. Virol. 84:6645. PubMed
  5. Wang X, et al. 2010. Haematologica. 95:884. (FC) PubMed
  6. Walker JD, et al. 2009. J. Immunol. 182:1548. (Block) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Hansen A, et al. 2002. Arthritis Rheum. 46:2160. (IHC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Sipe CJ, et al. 2022. Int J Mol Sci. 23:. PubMed
  2. Merah-Mourah F, et al. 2021. Curr Protoc. 1:e229. PubMed
  3. SoRelle ED, et al. 2022. Front Immunol. 13:1001145. PubMed
  4. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  5. Basnett J, et al. 2017. PLoS One. . 10.1371/journal.pone.0188042. PubMed
  6. Chabi S, et al. 2020. Cell Reports. 29(8):2307-2320.e6.. PubMed
  7. Ye Y, et al. 2022. Nat Commun. 13:6458. PubMed
  8. Malik-Chaudhry HK, et al. 2021. MAbs. 13:1890411. PubMed
  9. SoRelle ED, et al. 2022. Cell Rep. 40:111286. PubMed
  10. Matsui K, et al. 2015. PLoS One. 10: 0137195. PubMed
  11. Richardson SE, et al. 2021. STAR Protocols. 2(2):100420. PubMed
  12. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  13. Serra–Peinado C, et al. 2019. Nat Commun. 10:3705. PubMed
  14. Huang Y, et al. 2020. Cancer Cell. 36(6):630-644.e9.. PubMed
  15. Schlicher L, et al. 2022. Int J Mol Sci. 23:. PubMed
  16. Mondala PK, et al. 2021. Cell Stem Cell. 28(4):623-636.e9. PubMed
  17. Frame JM, et al. 2020. Developmental Cell. 55(2):133-149.e6. PubMed
  18. Vereertbrugghen A, et al. 2021. Front Oncol. 11:598319. PubMed
  19. Kim ST, et al. 2022. Nat Commun. 13:1970. PubMed
  20. Kan S, et al. 2020. Int J Oncol. 57:1047. PubMed
  21. Abdul-Jawad S, et al. 2021. Cancer Cell. 39(2):257-275.e6. PubMed
  22. Laing AG, et al. 2020. Nat Med. 26:1623. PubMed
  23. McComb S, et al. 2016. Sci Transl Med. 8: 339ra70. PubMed
  24. White C, et al. 2014. J Immunol. 193:5933. PubMed
  25. Xiao X, et al. 2019. Cell Discov. 5:2. PubMed
  26. Zirbes A, et al. 2021. J Mammary Gland Biol Neoplasia. 26:247. PubMed
  27. Moquin-Beaudry G, et al. 2022. Cell Rep Methods. 2:100153. PubMed
  28. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  29. Cho A, et al. 2019. Cell Rep. 28:909. PubMed
  30. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  31. Lu P, et al. 2021. Blood Cancer J. 11:39. PubMed
  32. Amanat F, et al. 2021. Cell. 184:3936. PubMed
  33. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  34. Japp AS, et al. 2021. Cell. 184(3):827-839.e14. PubMed
  35. Jackson-Jones LH, et al. 2020. Immunity. 52:700. PubMed
  36. BÖiers C, et al. 2018. Dev Cell. 44:362. PubMed
  37. Shen J, et al. 2021. Sci Adv. 7:eabi9787. PubMed
  38. Jing Y, et al. 2021. Signal Transduct Target Ther. 6:345. PubMed
  39. Kreye J, et al. 2020. Cell. 183(4):1058-1069.e19. PubMed
  40. Wang X, et al. 2021. Front Endocrinol (Lausanne). 12:666195. PubMed
  41. Sureshchandra S, et al. 2021. iScience. 24:102690. PubMed
  42. Kreye J, et al. 2020. bioRxiv. . PubMed
  43. Bigler M, et al. 2015. PLoS One. 10: 0145635. PubMed
  44. Woodberry T, et al. 2017. Infect Immun. 85:e00986. PubMed
  45. Luong-Gardiol N, et al. 2019. Cancer Cell. 35:649. PubMed
  46. Velázquez–Avila M, et al. 2019. Leukemia. 33:1337. PubMed
  47. Palazzo A, et al. 2018. J Immunol. 200:2304. PubMed
  48. Caeser R, et al. 2021. Nat Protoc. 16:2499. PubMed
  49. Roider T, et al. 2021. Blood Adv. 5:5060. PubMed
  50. Sureshchandra S, et al. 2022. Cell Rep. 39:110938. PubMed
  51. Gu X, et al. 2022. Vaccines (Basel). 10:. PubMed
  52. Yamanaka M, et al. 2009. Glycobiology. 1.375694444. PubMed
  53. Wang L, et al. 2021. Microbiol Spectr. 9:e0124621. PubMed
  54. Madsen A, et al. 2020. Immunity. 53:852. PubMed
  55. Greiner V, et al. 2019. iScience. 0.75625. PubMed
  56. Zumaquero E, et al. 2019. Elife. 8. PubMed
  57. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  58. Khosravi-Maharlooei M, et al. 2021. J Autoimmun. 119:102612. PubMed
  59. Cai S, et al. 2022. Cell Biosci. 12:115. PubMed
  60. Joly P, et al. 2017. PLoS One. 12(6):e0180568. PubMed
  61. Turner JS, et al. 2020. Nature. 586:127. PubMed
  62. Zhang Q, et al. 2021. Bone Joint Res. 10:226. PubMed
  63. de Jonge K, et al. 2021. OncoImmunology. 10(1):1873585. PubMed
  64. Dangaj D, et al. 2019. Cancer Cell. 35:885. PubMed
  65. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  66. Han AR, et al. 2021. Int J Stem Cells. 14:203. PubMed
  67. Avsec D, et al. 2022. Cell Death Dis. 13:860. PubMed
  68. Sanchez HN, et al. 2020. Nat Commun. 0.5. PubMed
  69. Li W, et al. 2020. Immunity. 53(2):456-470. PubMed
  70. Saraiva DP, et al. 2018. Front Immunol. 2.184027778. PubMed
  71. Fisher JG, et al. 2021. Front Oncol. 11:785635. PubMed
  72. Jiang Q et al. 2019. Cancer cell. 35(1):81-94 . PubMed
  73. Kim ST, et al. 2021. J Immunother Cancer. 9:. PubMed
  74. Yu H, et al. 2021. Cell Death Dis. 13:1. PubMed
  75. Ruan Y, et al. 2022. Exp Ther Med. 23:47. PubMed
  76. Collison J, et al. 2015. J Immunol. 195: 1162-1170. PubMed
  77. Gomes AM, et al. 2018. Cell Rep. 25:2821. PubMed
  78. Theurich S et al. 2017. Cell metabolism. 26(1):171-184 . PubMed
  79. Lavaert M, et al. 2020. Immunity. 52(6):1088-1104. PubMed
  80. Turner JS, et al. 2021. Nature. 595:421. PubMed
  81. Zheng L, et al. 2020. Clin Cancer Res. 26:3694. PubMed
  82. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  83. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  84. Vora AA, et al. 2021. STAR Protocols. 2(2):100565. PubMed
RRID
AB_314237 (BioLegend Cat. No. 302207)
AB_314238 (BioLegend Cat. No. 302208)
AB_2564142 (BioLegend Cat. No. 302254)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 95 kD
Distribution

B lineage (except plasma cells), follicular dendritic cells

Function
B cell activation and differentiation
Ligand/Receptor
Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor
Cell Type
B cells, Dendritic cells
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Tedder T, et al. 1994. Immunol. Today 15:437.
2. Bradbury L, et al. 1993. J. Immunol. 151:2915.

Gene ID
930 View all products for this Gene ID
UniProt
View information about CD19 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD19 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD19 HIB19 FC
Biotin anti-human CD19 HIB19 FC
FITC anti-human CD19 HIB19 FC
PE anti-human CD19 HIB19 FC
PE/Cyanine5 anti-human CD19 HIB19 FC
Purified anti-human CD19 HIB19 FC,CyTOF®,IHC-F
APC/Cyanine7 anti-human CD19 HIB19 FC
PE/Cyanine7 anti-human CD19 HIB19 FC
Alexa Fluor® 488 anti-human CD19 HIB19 FC,ICC
Alexa Fluor® 647 anti-human CD19 HIB19 FC,IHC-F
Pacific Blue™ anti-human CD19 HIB19 FC
Alexa Fluor® 700 anti-human CD19 HIB19 FC
PerCP anti-human CD19 HIB19 FC
PerCP/Cyanine5.5 anti-human CD19 HIB19 FC
Brilliant Violet 421™ anti-human CD19 HIB19 FC,ICC,IHC-F
Brilliant Violet 570™ anti-human CD19 HIB19 FC
Brilliant Violet 650™ anti-human CD19 HIB19 FC
Brilliant Violet 785™ anti-human CD19 HIB19 FC
Brilliant Violet 510™ anti-human CD19 HIB19 FC
Brilliant Violet 605™ anti-human CD19 HIB19 FC
Brilliant Violet 711™ anti-human CD19 HIB19 FC
Purified anti-human CD19 (Maxpar® Ready) HIB19 FC,CyTOF®
Alexa Fluor® 594 anti-human CD19 HIB19 ICC,IHC-F
PE/Dazzle™ 594 anti-human CD19 HIB19 FC
PE anti-human CD19 HIB19 FC
APC/Fire™ 750 anti-human CD19 HIB19 FC
Pacific Blue™ anti-human CD19 HIB19 FC
APC anti-human CD19 HIB19 FC
PE/Cyanine7 anti-human CD19 HIB19 FC
TotalSeq™-A0050 anti-human CD19 HIB19 PG
Brilliant Violet 750™ anti-human CD19 HIB19 FC
TotalSeq™-B0050 anti-human CD19 HIB19 PG
TotalSeq™-C0050 anti-human CD19 HIB19 PG
PerCP/Cyanine5.5 anti-human CD19 HIB19 FC
Spark NIR™ 685 anti-human CD19 HIB19 FC
Ultra-LEAF™ Purified anti-human CD19 HIB19 FC,CyTOF®,Block,IHC
APC/Fire™ 810 anti-human CD19 HIB19 FC
PE/Fire™ 640 anti-human CD19 HIB19 FC
PE/Fire™ 700 anti-human CD19 HIB19 FC
TotalSeq™-D0050 anti-human CD19 HIB19 PG
Spark YG™ 593 anti-human CD19 HIB19 FC
GMP Pacific Blue™ anti-human CD19 HIB19 FC
Spark Violet™ 423 anti-human CD19 HIB19 FC
GMP PE anti-human CD19 HIB19 FC
GMP APC anti-human CD19 HIB19 FC
KIRAVIA Blue 520™ anti-human CD19 HIB19 FC
GMP PerCP/Cyanine5.5 anti-human CD19 HIB19 FC
GMP PE/Cyanine7 anti-human CD19 HIB19 FC
Spark Violet™ 500 anti-human CD19 HIB19 FC
PE/Fire™ 810 anti-human CD19 HIB19 FC
Spark Violet™ 423 anti-human CD19 HIB19 FC
Spark UV™ 387 anti-human CD19 HIB19 FC
APC/Fire™ 750 anti-human CD19 HIB19 FC
PE/Cyanine5 anti-human CD19 HIB19 FC
Alexa Fluor® 660 anti-human CD19 HIB19 FC
PerCP/Fire™ 806 anti-human CD19 HIB19 FC
PerCP/Fire™ 780 anti-human CD19 HIB19 FC
Spark PLUS UV™ 395 anti-human CD19 HIB19 FC
Spark Red™ 718 anti-human CD19 HIB19 FC
Go To Top Version: 2    Revision Date: 12/18/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account